ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0580

Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting

Kevin Ong1, Jack Farr2, Louis McIntyre3, Andrew Gudeman2, Iain Murray4, Charles Hummer5, Wilson Ngai6, Heather Good7, Edmund Lau8 and Roy Altman9, 1Exponent, Philadelphia, 2Indiana University Department of Orthopaedic Surgery, Indianapolis, 3US Orthopedics, Tarrytown, 4Department of Orthopaedics, The University of Edinburgh, Edinburgh, United Kingdom, 5Premier Orthopaedics and Sports Medicine, Glen Mills, 6Sanofi US, Bridgewater, 7Sanofi US, Bridgewater, FL, 8Exponent, Menlo Park, 9David Geffen School of Medicine, University of California, Agua Dulce, CA

Meeting: ACR Convergence 2020

Keywords: Administrative Data, Health Services Research, Hyaluronan, Inflammation, pseudogout

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: Health Services Research Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Case reports of severe acute localized reactions (SALR) following intra-articular (IA) hyaluronic acid (HA) injections for knee osteoarthritis (OA) have been described. These have been speculated to be related to the crosslink of hylan or an allergic reaction to avian-derived hyaluronan, but reactions have also been reported for non-crosslinked, non-animal, and/or naturally derived HA. We compared surrogate SALR measures between patients using hylan G-F 20 and specific non-hylan G-F 20 HA products.

Methods: Knee OA patients were identified from the Optum Clinformatics dataset (Jan 2006-June 2016), stratified into hylan G-F 20 and non-hylan G-F 20 HA users, matched by single or multiple injection products. Occurrences of surrogate SALR measures including inflammation/infection, intra-articular corticosteroid (CS) injections, arthrocentesis/aspiration, arthrotomy/incision and drainage, arthroscopy, and office visits were evaluated (with ICD/CPT codes) within three days of HA use, adjusting for demographics and clinical factors. These were stratified by single/multiple injection products and evaluated for claims that had a corresponding knee OA diagnosis (knee OA related), as well as those that did not (any diagnosis).

Results: A total of 694,404 HA injections were included in the study. Inflammation/infection rate (with any diagnosis) was rare within three days of HA use (hylan G-F 20 (3-injection): 0.02%; Euflexxa: 0.03%; Hyalgan/Supartz: 0.02%; Orthovisc: 0.02%; hylan G-F 20 (1-injection): 0.02%; Monovisc: none; Gel-One: none) (Figs. 1 and 2); no statistical differences between hylan G-F 20 and non-hylan G-F 20 groups were observed (Table 1). The risk of arthrocentesis was greater for hylan G-F 20 (3-injection; 1.4%) than Euflexxa patients (1.1%) (adjusted hazard ratio (AHR) 1.48; p< 0.001), but lower than Hyalgan/Supartz (2.9%) (AHR 0.53; p< 0.001) and Orthovisc (2.4%) (AHR 0.80; p< 0.001) patients. When considering the collective occurrence of any of the surrogate SALR outcomes, the risk was found to be similar between hylan G-F 20 (3-injection) and Euflexxa cohorts (p=0.062), except when limited to those with corresponding knee OA diagnoses (AHR 1.24 for hylan G-F 20; p< 0.001). The overall risks were lower for hylan G-F 20 (3-injection) than Hyalgan/Supartz (p< 0.001) or Orthovisc (p< 0.001) patients and lower for hylan G-F 20 (1-injection) than Monovisc (p< =0.007) or Gel-One patients (p< =0.012).

Conclusion: The present study examined potential SALR risk in a real-world setting of almost 700,000 HA injections. Diagnoses of inflammation or infection diagnoses were extremely rare (0 to 0.03%) within three days of HA injections. While our arthrocentesis results are consistent with a randomized controlled trial (Kirchner 2006), which reported a greater rate of local reactions in terms of effusions, in hylan G-F 20 (3-injection) than Euflexxa patients, the collective risk of any of the surrogate SALR outcomes was not found to be significantly different between hylan G-F 20 and non-hylan G-F 20 products (single or multiple injection products).

Figure 1. Surrogate SALR outcomes within three days post-injection for hylan G-F 20 (3-injection), Euflexxa, Hyalgan/Supartz, and Orthovisc patient groups (top: outcomes with any diagnosis on the claims; bottom: outcomes with knee OA diagnosis on the claims). Statistically significant differences are indicated with an asterisk (* p < 0.05; green and red for lower and greater adjusted risks in the hylan G-F 20 (3-injection) group, respectively).

Figure 2. Surrogate SALR outcomes within three days post-injection for hylan G-F 20 (1-injection), Monovisc, and Gel-One patient groups (top: outcomes with any diagnosis on the claims; bottom: outcomes with knee OA diagnosis on the claims). Statistically significant differences are indicated with an asterisk (* p < 0.05; green and red for lower and greater adjusted risks in the hylan G-F 20 (1-injection) group, respectively).

Figure 3. Adjusted likelihood of clinical encounters within three days post-injection for the hylan G-F 20 groups compared to other non-hylan G-F 20 product groups, stratified by single and multiple injection products. The reference group for each comparison is the non-hylan G-F 20 group. [AHR: adjusted hazard ratio; KOA: knee osteoarthritis; ER: emergency room; Urg care: urgent care; CS: corticosteroid; IP: inpatient; OP: outpatient; I&D: incision and drainage]


Disclosure: K. Ong, Medtronic, 9, Sanofi, 9, Ferring Pharmaceuticals, 9, Pacira Pharmaceuticals, 9, Relievant Medsystems, 9, International Society for the Advancement of Spine Surgery, 9, SI-Technology, LLC, 9, Zimmer Biomet, 9, Ethicon, 9, Karl Storz Endoscopy-America, 9, Rex Medical, 9; J. Farr, Organogenesis, 2, 5, 7, 8, Zimmer Biomet, 2, Samumed, 2, Novartis, 2, Fidia Pharma, 2; L. McIntyre, AAOS, 6, Active Implants, 5, Advocacy for Improvement in Mobility, 6, Arthroscopy Association of North America, 6, Delegate Medical Society of the State of New York, 6, Embody, 5, 7, Flexion, 5, Mininvasive, 5, Orthopedic Practice Management, Inc, 6, Orthopedics Today, 6, Sanofi-Aventis, 8, Smith & Nephew, 5, 8, Westchester County Medical Society, 6; A. Gudeman, None; I. Murray, Bone and Joint Research, 6, British Orthopaedic Research Society, 6, Journal of Bone and Joint Surgery - British, 6; C. Hummer, Sanofi, Flexion Therapeutics, 5, AAOS Board of Councilors, 6; W. Ngai, sanofi, 1, 3; H. Good, Sanofi, 1, 3; E. Lau, Medtronic, 9, Stryker Orthopaedics, 9, Sanofi, 9, Ferring Pharmaceuticals, 9, Paradigm Spine, 9, Boston Scientific, 9, Pacira Pharmaceuticals, 9, Alcon, 9, Relievant Medsystems, 9, American Association of Orthopaedic Surgeons, 9; R. Altman, GlaxoSmithKline, 5, Norvartis, 5, Pfizer, 5, Sanofi-Aventis, 9.

To cite this abstract in AMA style:

Ong K, Farr J, McIntyre L, Gudeman A, Murray I, Hummer C, Ngai W, Good H, Lau E, Altman R. Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/risk-of-severe-acute-localized-reactions-for-different-intra-articular-hyaluronic-acid-knee-injections-in-a-real-world-setting/. Accessed January 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-severe-acute-localized-reactions-for-different-intra-articular-hyaluronic-acid-knee-injections-in-a-real-world-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.